Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2859-2865

  Truin, W ^a   Voogd, A C ^b,c   Vreugdenhil, G ^a   van der Heiden van der Loo, M ^d   Siesling, S ^e,f   Roumen, R M ^a  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c The Netherlands   (Netherlands)

^d Department of Research and Registration   (Netherlands)

^e Integraal Kankercentrum Stedendriehoek Twente   (Netherlands)

^f UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Adjuvant chemotherapy; Histology; Hormonal treatment; Invasive ductal carcinoma; Invasive lobular carcinoma; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER REGISTRY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LOBULAR BREAST CANCER; MAJOR CLINICAL STUDY; NETHERLANDS; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; POSTMENOPAUSE; SURVIVAL RATE;

EID: 84868140149     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds180     Document Type: Article

References (33)

1. Silverstein MJ, Lewinsky BS, Waisman JR et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 1994; 73(6): 1673-1677.
2. The World Health Organization. The World Health Organization histological typing of breast tumors, second edition. Am J Clin Pathol 1982; 78(6): 806-816.
3. Yeatman TJ, Cantor AB, Smith TJ et al. Tumor biology of infiltrating lobular carcinoma: implications for management. Ann Surg 1995; 222(4): 549-559.
4. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005; 93(9): 1046-1052.
5. Pestalozzi BC, Zahrieh D, Mallon E et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast; combined results of 15 international breast cancer study group clinical trials. J Clin Oncol 2008; 26(18): 3006-3014.
6. Kaufmann M, von Minckwitz G, Smith R et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003; 21(13): 1059-1070.
7. Chia S, Swain SM, Byrd DR et al. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008; 26(5): 786-790.
8. Anderson ED, Forrest AP, Hawkins RA et al. Primary systemic therapy for operable breast cancer. Br J Cancer 1991; 63(4): 561-566.
9. Mieog JSD, van der Hage JA, van de Velde CJH. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007; 94(10): 1189-1200.
10. Fisher B, Bryant J, Wolmark N. et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16(8): 2672-2685.
11. Cocquyt VF, Blondeel PN, Depypere HT et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinomas. Eur J Surg Oncol 2003; 29(4): 361-367.
12. Cristofanilli M, Gonzalez-Angulo A, Sneige N et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005; 23(1): 41-48.
13. Tubiana-Hulin M, Stevens D, Lasry S et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 2006; 17(8): 1228-1233.
14. Katz A, Saad ED, Porter P et al. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 2007; 8(1): 55-62.
15. Farese SA, Aebi S. Infiltrating lobular carcinoma of the breast: systemic treatment. Breast Disease 2009; 30: 45-52.
16. Purushotham A, Pinder S, Cariati M et al. Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast? J Clin Oncol 2010; 28(22): 3552-3554.
17. Truin W, Voogd AC, Vreugdenhil G et al. Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer. Breast 2011; 20(6): 505-509.
18. Schouten LJ, Jager JJ, van den Brandt PA. Quality of cancer registry data: a comparison of data provided by clinicians with those of registrations personnel. Br J Cancer 1993; 68(5): 974-977.
19. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472): 1687-1717.
20. Rutgers EJ, Nortier JW, Tuut MK et al. Dutch Institute for Healthcare Improvement guideline, "Treatment of breast cancer". Ned Tijdschr Geneeskd 2002; 146(45): 2144-2151.
21. World Health Organization. International Classification of Diseases, 10th edition. Geneva: 1998.
22. Adjuvant! Online: Homepage, http://www.adjuvantonline.com (1 December 2011, date last accessed).
23. Rakha EA, El-Sayed ME, Powe DG et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 2008; 44(1): 73-83.
24. Altundag K, Altundag O, Akyurek S et al. Inactivation of E-cadherin and less sensitivity of lobular breast carcinoma cells to chemotherapy. Breast 2006; 15(3): 300.
25. Bertucci F, Orsetti B, Nègre V et al. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008; 27(40): 5359-5372.
26. Buttitta F, Felicioni L, Barassi F et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 2006; 208(3): 350-355.
27. Barbareschi M, Buttitta F, Felicioni L et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007; 13(20): 6064-6069.
28. Isakoff SJ, Engelman JA, Irie HY et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005; 65(23): 10992-11000.
29. Bharat A, Gao F, Margenthaler JA. Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers. Am J Surg 2009; 198(4): 516-519.
30. Rakha EA, Gill MS, El-Sayed ME et al. The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. Breast Cancer Res Treat 2009; 114(2): 243-250.
31. Monhollen L, Morrison C, Ademuyiwa FO et al. Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type. Histopathology 2012. April 4 [Epub ahead of print] doi: 10.1111/j.1365-2559.2012.04230.x.
32. Van de Vijver MJ, He YD, van 't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Eng J Med 2002; 347(25): 1999-2009.
33. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Eng J Med 2004; 351(27): 2817-2826.